当前位置: 首页 >> 检索结果
1. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy.
作者: Michal Tendera.;Olivier Chassany.;Roberto Ferrari.;Ian Ford.;Philippe Gabriel Steg.;Jean-Claude Tardif.;Kim Fox.; .
来源: Circ Cardiovasc Qual Outcomes. 2016年9卷1期31-8页
To explore the effect of ivabradine on angina-related quality of life (QoL) in patients participating in the Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) QoL substudy.
2. Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
作者: Connie N Hess.;Tracy Y Wang.;Lisa A McCoy.;John C Messenger.;Mark B Effron.;Marjorie E Zettler.;Timothy D Henry.;Eric D Peterson.;Gregg C Fonarow.
来源: Circulation. 2016年133卷5期493-501页
Previous studies examining early readmission after acute myocardial infarction have focused exclusively on inpatient readmissions. However, from a patient's perspective, any unplanned inpatient or observation rehospitalization after acute myocardial infarction represents a significant event; these unplanned rehospitalizations have not been well characterized.
3. Novel 6p21.3 Risk Haplotype Predisposes to Acute Coronary Syndrome.
作者: Juha Sinisalo.;Efthymia Vlachopoulou.;Marja Marchesani.;Johanna Nokelainen.;Mikko I Mäyränpää.;Jani Lappalainen.;Riitta Paakkanen.;Annika Wennerström.;Krista Salli.;Heikki J Niemi.;Satu Männistö.;Perttu Salo.;Juhani Junttila.;Markku Eskola.;Kjell Nikus.;T Petteri Arstila.;Markus Perola.;Heikki Huikuri.;Pekka J Karhunen.;Petri T Kovanen.;Aarno Palotie.;Aki S Havulinna.;Carla Lluis-Ganella.;Jaume Marrugat.;Roberto Elosua.;Veikko Salomaa.;Markku S Nieminen.;Marja-Liisa Lokki.
来源: Circ Cardiovasc Genet. 2016年9卷1期55-63页
The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronary syndrome. Genome-wide association studies have revealed associations with human leukocyte antigen and non-human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allelic level.
4. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
作者: Jonathan P Piccini.;Anne S Hellkamp.;Jeffrey B Washam.;Richard C Becker.;Günter Breithardt.;Scott D Berkowitz.;Jonathan L Halperin.;Graeme J Hankey.;Werner Hacke.;Kenneth W Mahaffey.;Christopher C Nessel.;Daniel E Singer.;Keith A A Fox.;Manesh R Patel.
来源: Circulation. 2016年133卷4期352-60页
Patients with atrial fibrillation (AF) often take multiple medications.
5. Long-Term Clinical Outcomes of Fractional Flow Reserve-Guided Versus Routine Drug-Eluting Stent Implantation in Patients With Intermediate Coronary Stenosis: Five-Year Clinical Outcomes of DEFER-DES Trial.
作者: Sang Hyun Park.;Ki-Hyun Jeon.;Joo Myung Lee.;Chang-Wook Nam.;Joon-Hyung Doh.;Bong-Ki Lee.;Seung-Woon Rha.;Ki-dong Yoo.;Kyung Tae Jung.;Young-Seok Cho.;Hae-Young Lee.;Tae-Jin Youn.;Woo-Young Chung.;Bon-Kwon Koo.
来源: Circ Cardiovasc Interv. 2015年8卷12期e002442页
We aimed to compare the long-term clinical outcomes between fractional flow reserve (FFR)-guided and routine drug-eluting stent (DES) implantation in patients with an intermediate coronary stenosis.
6. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).
作者: Lauren B Cooper.;Robert J Mentz.;Jie-Lena Sun.;Phillip J Schulte.;Jerome L Fleg.;Lawton S Cooper.;Ileana L Piña.;Eric S Leifer.;William E Kraus.;David J Whellan.;Steven J Keteyian.;Christopher M O'Connor.
来源: Circ Heart Fail. 2015年8卷6期1044-51页
Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients. We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.
7. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.
作者: L Maria Belalcazar.;George D Papandonatos.;Bahar Erar.;Inga Peter.;Hadeel Alkofide.;Ashok Balasubramanyam.;Ariel Brautbar.;Steven E Kahn.;William C Knowler.;Christie M Ballantyne.;Jeanne M McCaffery.;Gordon S Huggins.; .
来源: Circ Cardiovasc Genet. 2016年9卷1期71-8页
Glucokinase regulatory protein (GCKR) inhibitors offer a novel treatment approach for glucose control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern. GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP.
8. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
作者: Karen P Alexander.;Giora Weisz.;Kristi Prather.;Stefan James.;Daniel B Mark.;Kevin J Anstrom.;Linda Davidson-Ray.;Adam Witkowski.;Angel J Mulkay.;Anna Osmukhina.;Ramin Farzaneh-Far.;Ori Ben-Yehuda.;Gregg W Stone.;E Magnus Ohman.
来源: Circulation. 2016年133卷1期39-47页
Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI patients.
9. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
作者: Stephen D Persell.;Tiffany Brown.;Ji Young Lee.;Shreya Shah.;Eric Henley.;Timothy Long.;Stephanie Luther.;Donald M Lloyd-Jones.;Muriel Jean-Jacques.;Namratha R Kandula.;Thomas Sanchez.;David W Baker.
来源: Circ Cardiovasc Qual Outcomes. 2015年8卷6期560-6页
Many eligible primary cardiovascular disease prevention candidates are not treated with statins. Electronic health record data can identify patients with increased cardiovascular disease risk.
10. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.
作者: Mark J Eisenberg.;Sarah B Windle.;Nathalie Roy.;Wayne Old.;François R Grondin.;Iqbal Bata.;Ayman Iskander.;Claude Lauzon.;Nalin Srivastava.;Adam Clarke.;Daniel Cassavar.;Danielle Dion.;Herbert Haught.;Shamir R Mehta.;Jean-François Baril.;Charles Lambert.;Mina Madan.;Beth L Abramson.;Payam Dehghani.; .
来源: Circulation. 2016年133卷1期21-30页
Less than one-third of smokers hospitalized with an acute coronary syndrome (ACS) remain abstinent following discharge. We assessed whether varenicline, begun in-hospital, is efficacious for smoking cessation following ACS.
11. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study.
作者: Shao-Liang Chen.;Hang Zhang.;Du-Jiang Xie.;Juan Zhang.;Ling Zhou.;Alexander M K Rothman.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2015年8卷11期e002837页
The mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated. This study aimed to analyze the hemodynamic, functional, and clinical responses to PADN in patients with PAH of different causes.
12. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
作者: Stephen A O'Connor.;Julien Amour.;Anne Mercadier.;Réjane Martin.;Mathieu Kerneis.;Jérémie Abtan.;Delphine Brugier.;Johanne Silvain.;Olivier Barthélémy.;Pascal Leprince.;Gilles Montalescot.;Jean-Philippe Collet.; .
来源: Circ Cardiovasc Interv. 2015年8卷11期e002786页
Allogenic platelet transfusions (PT) are administered to treat excessive bleeding in patients on P2Y12 receptor inhibitors (RI). We assessed the effect of ex vivo and in vivo PT on platelet activation and aggregation in patients on dual antiplatelet therapy.
13. Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease.
作者: Sandra Guauque-Olarte.;David Messika-Zeitoun.;Arnaud Droit.;Maxime Lamontagne.;Joël Tremblay-Marchand.;Emilie Lavoie-Charland.;Nathalie Gaudreault.;Benoit J Arsenault.;Marie-Pierre Dubé.;Jean-Claude Tardif.;Simon C Body.;Jonathan G Seidman.;Catherine Boileau.;Patrick Mathieu.;Philippe Pibarot.;Yohan Bossé.
来源: Circ Cardiovasc Genet. 2015年8卷6期812-22页
Calcific aortic valve stenosis (AS) is a life-threatening disease with no medical therapy. The genetic architecture of AS remains elusive. This study combines genome-wide association studies, gene expression, and expression quantitative trait loci mapping in human valve tissues to identify susceptibility genes of AS.
14. Effect of Short-Term Steroid Therapy on Early Recurrence During the Blanking Period After Catheter Ablation of Atrial Fibrillation.
作者: Yoo Ri Kim.;Gi-Byoung Nam.;Seungbong Han.;Sung-Hwan Kim.;Ki-Hun Kim.;Sulhee Lee.;Jun Kim.;Kee-Joon Choi.;You-Ho Kim.
来源: Circ Arrhythm Electrophysiol. 2015年8卷6期1366-72页
Early recurrence (ER) of atrial tachyarrhythmias during the first 3 months (blanking period) after atrial fibrillation ablation can be highly symptomatic, often requiring emergency treatment. Short-term steroid therapy may suppress ER during the blanking period.
15. Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia.
作者: Hertzel C Gerstein.;Guillaume Paré.;Matthew J McQueen.;Heinz Haenel.;Shun Fu Lee.;Janice Pogue.;Aldo P Maggioni.;Salim Yusuf.;Sibylle Hess.; .
来源: Circulation. 2015年132卷24期2297-304页
Serum biomarkers may identify people at risk for cardiovascular (CV) outcomes. Biobanked serum samples from 8494 participants with dysglycemia in the completed Outcome Reduction With Initial Glargine Intervention trial were assayed for 284 biomarkers to identify those that could identify people at risk for a CV outcome or death when added to clinical measurements.
16. Functional Genomics Analysis of Big Data Identifies Novel Peroxisome Proliferator-Activated Receptor γ Target Single Nucleotide Polymorphisms Showing Association With Cardiometabolic Outcomes.
作者: Kris Richardson.;Gavin R Schnitzler.;Chao-Qiang Lai.;Jose M Ordovas.
来源: Circ Cardiovasc Genet. 2015年8卷6期842-51页
Cardiovascular disease and type 2 diabetes mellitus represent overlapping diseases where a large portion of the variation attributable to genetics remains unexplained. An important player in their pathogenesis is peroxisome proliferator-activated receptor γ (PPARγ) that is involved in lipid and glucose metabolism and maintenance of metabolic homeostasis. We used a functional genomics methodology to interrogate human chromatin immunoprecipitation-sequencing, genome-wide association studies, and expression quantitative trait locus data to inform selection of candidate functional single nucleotide polymorphisms (SNPs) falling in PPARγ motifs.
17. Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients' and Providers' Perspectives.
作者: Carole Decker.;Emily Chhatriwalla.;Elizabeth Gialde.;Brian Garavalia.;Debbie Summers.;Miriam E Quinlan.;Eric Cheng.;Marilyn Rymer.;Jeffrey L Saver.;Er Chen.;David M Kent.;John A Spertus.
来源: Circ Cardiovasc Qual Outcomes. 2015年8卷6 Suppl 3期S109-16页
National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients' functional recovery. However, 23% to 40% of ideal candidates with acute ischemic stroke for reperfusion are not treated, perhaps because of the difficulty in explaining the benefits and risks of r-tPA within the frenetic pace of emergency department care. To support better knowledge transfer and creation of a shared decision-making tool, we conducted qualitative interviews to define the information needs and preferred presentation format for stroke survivors, caregivers, and clinicians considering r-tPA treatment.
18. Right Atrial Function in Pulmonary Arterial Hypertension.
作者: Gabriela Querejeta Roca.;Patricia Campbell.;Brian Claggett.;Scott D Solomon.;Amil M Shah.
来源: Circ Cardiovasc Imaging. 2015年8卷11期e003521; discussion e003521页
Elevated right atrial (RA) pressure is an established prognostic measure in pulmonary arterial hypertension (PAH). However, little is known about perturbations in RA function in PAH.
19. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
作者: Ioana R Preston.;Kari E Roberts.;Dave P Miller.;Ginny P Sen.;Mona Selej.;Wade W Benton.;Nicholas S Hill.;Harrison W Farber.
来源: Circulation. 2015年132卷25期2403-11页
Long-term anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH). In contrast, limited data support anticoagulation in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH). We assessed the effect of warfarin anticoagulation on survival in IPAH and SSc-PAH patients enrolled in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a longitudinal registry of group I PAH.
20. Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: insights from the International Index of Microcirculatory Resistance Registry.
作者: Joo Myung Lee.;Jamie Layland.;Ji-Hyun Jung.;Hyun-Jung Lee.;Mauro Echavarria-Pinto.;Stuart Watkins.;Andy S Yong.;Joon-Hyung Doh.;Chang-Wook Nam.;Eun-Seok Shin.;Bon-Kwon Koo.;Martin K Ng.;Javier Escaned.;William F Fearon.;Keith G Oldroyd.
来源: Circ Cardiovasc Interv. 2015年8卷11期e002857页
The index of microcirculatory resistance (IMR) is a quantitative and specific index for coronary microcirculation. However, the distribution and determinants of IMR have not been fully investigated in patients with ischemic heart disease (IHD).
|